prikaz prve stranice dokumenta Impact of Reslizumab on Outcomes of Severe Asthmatic Patients: Current Perspectives
  Preuzmi
PDF 135.83 KB
Znanstveni rad - Pregledni rad
Impact of Reslizumab on Outcomes of Severe Asthmatic Patients: Current Perspectives
Patient Related Outcome Measures, 9 (2018); 267-273. https://doi.org/10.2147/PROM.S146966
Padilla Galo, Alicia; Labor, Marina; Tiotiu, Angelica; Baiardini, Ilaria; Scichilone, Nicola; Braido, Fulvio

Citirajte ovaj rad

Padilla Galo, A., Labor, M., Tiotiu, A., Baiardini, I., Scichilone, N. i Braido, F. (2018). Impact of Reslizumab on Outcomes of Severe Asthmatic Patients: Current Perspectives. Patient Related Outcome Measures, 9., 267-273. doi: 10.2147/PROM.S146966

Padilla Galo, Alicia, et al. "Impact of Reslizumab on Outcomes of Severe Asthmatic Patients: Current Perspectives." Patient Related Outcome Measures, vol. 9, 2018, str. 267-273. https://doi.org/10.2147/PROM.S146966

Padilla Galo, Alicia, Marina Labor, Angelica Tiotiu, Ilaria Baiardini, Nicola Scichilone i Fulvio Braido. "Impact of Reslizumab on Outcomes of Severe Asthmatic Patients: Current Perspectives." Patient Related Outcome Measures 9 (2018): 267-273. https://doi.org/10.2147/PROM.S146966

Padilla Galo, A., et al. (2018) 'Impact of Reslizumab on Outcomes of Severe Asthmatic Patients: Current Perspectives', Patient Related Outcome Measures, 9, str. 267-273. doi: 10.2147/PROM.S146966

Padilla Galo A, Labor M, Tiotiu A, Baiardini I, Scichilone N, Braido F. Impact of Reslizumab on Outcomes of Severe Asthmatic Patients: Current Perspectives. Patient Related Outcome Measures [Internet]. 2018. [pristupljeno 27.10.2024.];9:267-273. doi: 10.2147/PROM.S146966

A. Padilla Galo, M. Labor, A. Tiotiu, I. Baiardini, N. Scichilone i F. Braido, "Impact of Reslizumab on Outcomes of Severe Asthmatic Patients: Current Perspectives", Patient Related Outcome Measures, vol. 9, str. 267-273, 2018. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:239:222855. [Citirano: 27.10.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:239:222855
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)Impact of Reslizumab on Outcomes of Severe Asthmatic Patients: Current Perspectives
AutorAlicia Padilla Galo
AutorMarina Labor
MBZ: 357633
AutorAngelica Tiotiu
AutorIlaria Baiardini
AutorNicola Scichilone
AutorFulvio Braido
Autorova ustanova(Klinički bolnički centar Osijek)
Autorova ustanovaSveučilište Josipa Jurja Strossmayera u Osijeku
Medicinski fakultet Osijek
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Interna medicina
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Temeljne medicinske znanosti
Farmakologija
Sažetak (engleski)
Approximately 5%-10% of asthmatics suffer from severe asthma. New biological treatments represent a great opportunity to reduce asthma burden and to improve asthma patients' lives. Reslizumab will soon be available in several European countries. This anti-IL-5 IgG4/κ monoclonal antibody, administered intravenously at a dose of 3 mg/kg over 20-50 minutes every 4 weeks, has been shown to be safe and effective in patients with 400 eosinophils/μL or more in their peripheral blood. The clinical effects in reducing asthma exacerbations and in improving the quality of life and lung function are clear, but further research is needed to determine the best biological compound for a specific cluster of patients. Research data have shown that in patients who were expressing other clinical features of eosinophilic inflammation over asthma (rhinosinusitis and nasal polyposis), the clinical benefit of reslizumab was greater. Furthermore, it has also been observed that in patients with unsatisfactory response to mepolizumab, reslizumab is able to significantly improve the clinical and biological parameters. The aim of personalized medicine is to provide the right drug to the right patient at the right dose at the right moment. The biological treatments that were developed to modify specific pathological pathways not only provide us with the tools for the management of asthma patients but also clarify the biological mechanisms involved in its pathogenesis.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Pregledni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran - međunarodna recenzija
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaPatient Related Outcome Measures
Brojčani podacivol. 9, str. 267-273
e-ISSN1179-271X
DOIhttps://doi.org/10.2147/PROM.S146966
URN:NBNurn:nbn:hr:239:222855
Datum objave publikacije2018
URL dokumentahttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6103306/
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Imenovanje-Nekomercijalno 4.0 međunarodna (CC BY-NC 4.0)
Datum i vrijeme pohrane2019-11-07 12:14:09